SmokingNCT02724462
Trial of An Innovative Smartphone Intervention for Smoking Cessation
A study testing Smartphone-delivered Intervention (SmartQuit) in people with Smoking, run by Fred Hutchinson Cancer Center at 1 site in United States.
Trial summary
The goal of this study is to determine whether the novel smartphone app (SmartQuit) provides higher quit rates than the current standard smoking cessation app. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Smoking
- What is being tested?
- Smartphone-delivered Intervention (SmartQuit)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,503 participants
- Where
- 1 siteUnited States
- Study dates
- 27 May 2017to 27 Dec 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- age 18 or older
- smokes at least five cigarettes daily for at least past 12 months
- wants to quit cigarette smoking in the next 30 days
- if concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days
- interested in learning skills to quit smoking
- willing to be randomly assigned to either condition
Show all 13Show fewer
- resides in US
- has at least daily access to their own personal Apple iPhone, Android, or Windows Phone
- knows how to login and download a smartphone application
- willing and able to read in English
- not using other smoking cessation interventions (including apps or our other intervention studies).
- willing to complete all three follow-up surveys
- provide email, phone, and mailing address.
Who cannot join
- The exclusion criteria are opposite of the inclusion criteria listed above.
Trial locations and contacts
1 site in 1 country.
United States1 site
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
About this study
Official title: Randomized Trial of An Innovative Smartphone Intervention for Smoking Cessation
The goal of this study is to determine whether the novel smartphone app (SmartQuit) provides higher quit rates than the current standard smoking cessation app.
- Conditions
- Smoking
- Being tested
- Smartphone-delivered Intervention (SmartQuit), : Smartphone-delivered Intervention (Standard of care app)
- Keywords
- smoking cessation, app for quitting smoking
- Medical subject headings
- Smoking, Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Smartphone-delivered Intervention (SmartQuit)Behavioural
The experimental arm includes an intervention using a novel smartphone smoking cessation app.
: Smartphone-delivered Intervention (Standard of care app)Behavioural
The control intervention uses a standard of care smartphone smoking cessation app.
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study. Receives: Behavioral: Smartphone-delivered Intervention (SmartQuit) |
| Control | Active comparator | This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study. Receives: Behavioral: : Smartphone-delivered Intervention (Standard of care app) |
What is being measured
The primary outcome is the main question the study is designed to answer.
30-day Point Prevalence Abstinence, Complete-case
Percentage of participants reporting no smoking in the past 30 days, 12 months post-treatment. Participants missing follow-up data are excluded for the complete-case analysis. Exact 2-sided CI was based on the observed proportion of participants.
Measured: 12 months post randomization
Secondary outcomes (1)
30-day Point Prevalence Abstinence, Missing=Smoking Imputation
Percentage of participants reporting no smoking in the past 30 days, 12 months post-treatment. Participants missing follow-up data are imputed as still smoking. Exact 2-sided CI was based on the observed proportion of participants.
Measured: 12 months post randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2016 (estimated)
- Study start27 May 2017
- Primary completion27 Dec 2019
- Study completion27 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for SmokingStudies of the same condition, open and under way.
- More trials run by Fred Hutchinson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 2,503 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fred Hutchinson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- University of Washington, National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Jonathan Bricker, Ph.D., Principal investigator, Fred Hutchinson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02724462
- Sponsor's protocol ID
- 8317
- Other IDs
- NCI-2018-02662, RG1001191, R01CA192849
- Status last verified
- Nov 2020
- First submitted
- 24 Mar 2016
- Last updated
- 5 Jan 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Santiago-Torres M, Mull KE, Shi D, Alexander AC, Nollen NL, Sullivan BM, Zvolensky MJ, Bricker JB. Intersectionality in cigarette smoking cessation: A latent class analysis to predict 12-month cessation in a randomized controlled trial. Addiction. 2026 Jan;121(1):173-185. doi: 10.1111/add.70185. Epub 2025 Sep 17.
PubMed 40963258Santiago-Torres M, Mull KE, Sullivan BM, Cupertino AP, Salloum RG, Triplette M, Zvolensky MJ, Bricker JB. Evaluating the Impact of Pharmacotherapy in Augmenting Quit Rates Among Hispanic Adults in an App-Delivered Smoking Cessation Intervention: Secondary Analysis of a Randomized Controlled Trial. JMIR Form Res. 2025 Jan 31;9:e69311. doi: 10.2196/69311.
PubMed 39889280Santiago-Torres M, Mull KE, Sullivan BM, Prochaska JJ, Zvolensky MJ, Bricker JB. Can an Acceptance and Commitment Therapy-Based Smartphone App Help Individuals with Mental Health Disorders Quit Smoking? Depress Anxiety. 2024;2024:1055801. doi: 10.1155/2024/1055801. Epub 2024 Jun 21.
PubMed 39845432Santiago-Torres M, Mull KE, Sullivan BM, Bricker JB. Use of e-Cigarettes in Cigarette Smoking Cessation: Secondary Analysis of a Randomized Controlled Trial. JMIR Mhealth Uhealth. 2023 Nov 9;11:e48896. doi: 10.2196/48896.
PubMed 37943594Jackson S, Brown J, Norris E, Livingstone-Banks J, Hayes E, Lindson N. Mindfulness for smoking cessation. Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD013696. doi: 10.1002/14651858.CD013696.pub2.
PubMed 35420700Santiago-Torres M, Mull KE, Sullivan BM, Ferketich AK, Bricker JB. Efficacy of an acceptance and commitment therapy-based smartphone application for helping rural populations quit smoking: Results from the iCanQuit randomized trial. Prev Med. 2022 Apr;157:107008. doi: 10.1016/j.ypmed.2022.107008. Epub 2022 Mar 4.
PubMed 35257698Santiago-Torres M, Mull KE, Sullivan BM, Kendzor DE, Bricker JB. Efficacy and utilization of smartphone applications for smoking cessation among low-income adults: Secondary analysis of the iCanQuit randomized trial. Drug Alcohol Depend. 2022 Feb 1;231:109258. doi: 10.1016/j.drugalcdep.2021.109258. Epub 2021 Dec 31.
PubMed 35026491Santiago-Torres M, Mull KE, Sullivan BM, Kwon D, Nollen NL, Zvolensky MJ, Bricker JB. Efficacy and utilization of an acceptance and commitment therapy-based smartphone application for smoking cessation among Black adults: secondary analysis of the iCanQuit randomized trial. Addiction. 2022 Mar;117(3):760-771. doi: 10.1111/add.15721. Epub 2021 Dec 9.
PubMed 34890104Bricker JB, Levin M, Lappalainen R, Mull K, Sullivan B, Santiago-Torres M. Mechanisms of Smartphone Apps for Cigarette Smoking Cessation: Results of a Serial Mediation Model From the iCanQuit Randomized Trial. JMIR Mhealth Uhealth. 2021 Nov 9;9(11):e32847. doi: 10.2196/32847.
PubMed 34751662Bricker JB, Watson NL, Mull KE, Sullivan BM, Heffner JL. Efficacy of Smartphone Applications for Smoking Cessation: A Randomized Clinical Trial. JAMA Intern Med. 2020 Nov 1;180(11):1472-1480. doi: 10.1001/jamainternmed.2020.4055.
PubMed 32955554
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Trial of An Innovative Smartphone Intervention for Smoking Cessation
- ClinicalTrials.gov ID
- NCT02724462
- Acronym / sponsor ID
- 8317
- Conditions
- Smoking
- Keywords
- smoking cessation, app for quitting smoking
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,503 participants (actual)
- Lead sponsor
- Fred Hutchinson Cancer CenterUniversity, hospital or other
- Collaborators
- University of Washington, National Cancer Institute (NCI)
- Study start
- 27 May 2017 (actual)
- Primary completion
- 27 Dec 2019 (actual)
- Study completion
- 27 Dec 2019 (actual)
- First posted
- 31 Mar 2016 (estimated)
- Results
- Posted 5 Jan 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to determine whether the novel smartphone app (SmartQuit) provides higher quit rates than the current standard smoking cessation app.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Behavioral: Smartphone-delivered Intervention (SmartQuit)This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study. |
| Control | Active comparator | Behavioral: : Smartphone-delivered Intervention (Standard of care app)This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- age 18 or older
- smokes at least five cigarettes daily for at least past 12 months
- wants to quit cigarette smoking in the next 30 days
- if concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days
- interested in learning skills to quit smoking
Key exclusion criteria (1 listed)
- The exclusion criteria are opposite of the inclusion criteria listed above.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Smartphone-delivered Intervention (SmartQuit)The experimental arm includes an intervention using a novel smartphone smoking cessation app. | Behavioural | Experimental |
| : Smartphone-delivered Intervention (Standard of care app)The control intervention uses a standard of care smartphone smoking cessation app. | Behavioural | Control |
Primary outcome
30-day Point Prevalence Abstinence, Complete-case
Time frame: 12 months post randomization
Percentage of participants reporting no smoking in the past 30 days, 12 months post-treatment. Participants missing follow-up data are excluded for the complete-case analysis. Exact 2-sided CI was based on the observed proportion of participants.
1 secondary outcome
30-day Point Prevalence Abstinence, Missing=Smoking Imputation
Time frame: 12 months post randomization
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40963258Santiago-Torres M, Mull KE, Shi D, Alexander AC, Nollen NL, Sullivan BM, Zvolensky MJ, Bricker JB. Intersectionality in cigarette smoking cessation: A latent class analysis to predict 12-month cessation in a randomized controlled trial. Addiction. 2026 Jan;121(1):173-185. doi: 10.1111/add.70185. Epub 2025 Sep 17.
- Derived from this study: PubMed 39889280Santiago-Torres M, Mull KE, Sullivan BM, Cupertino AP, Salloum RG, Triplette M, Zvolensky MJ, Bricker JB. Evaluating the Impact of Pharmacotherapy in Augmenting Quit Rates Among Hispanic Adults in an App-Delivered Smoking Cessation Intervention: Secondary Analysis of a Randomized Controlled Trial. JMIR Form Res. 2025 Jan 31;9:e69311. doi: 10.2196/69311.
- Derived from this study: PubMed 39845432Santiago-Torres M, Mull KE, Sullivan BM, Prochaska JJ, Zvolensky MJ, Bricker JB. Can an Acceptance and Commitment Therapy-Based Smartphone App Help Individuals with Mental Health Disorders Quit Smoking? Depress Anxiety. 2024;2024:1055801. doi: 10.1155/2024/1055801. Epub 2024 Jun 21.
- Derived from this study: PubMed 37943594Santiago-Torres M, Mull KE, Sullivan BM, Bricker JB. Use of e-Cigarettes in Cigarette Smoking Cessation: Secondary Analysis of a Randomized Controlled Trial. JMIR Mhealth Uhealth. 2023 Nov 9;11:e48896. doi: 10.2196/48896.
- Derived from this study: PubMed 35420700Jackson S, Brown J, Norris E, Livingstone-Banks J, Hayes E, Lindson N. Mindfulness for smoking cessation. Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD013696. doi: 10.1002/14651858.CD013696.pub2.
- Derived from this study: PubMed 35257698Santiago-Torres M, Mull KE, Sullivan BM, Ferketich AK, Bricker JB. Efficacy of an acceptance and commitment therapy-based smartphone application for helping rural populations quit smoking: Results from the iCanQuit randomized trial. Prev Med. 2022 Apr;157:107008. doi: 10.1016/j.ypmed.2022.107008. Epub 2022 Mar 4.
- Derived from this study: PubMed 35026491Santiago-Torres M, Mull KE, Sullivan BM, Kendzor DE, Bricker JB. Efficacy and utilization of smartphone applications for smoking cessation among low-income adults: Secondary analysis of the iCanQuit randomized trial. Drug Alcohol Depend. 2022 Feb 1;231:109258. doi: 10.1016/j.drugalcdep.2021.109258. Epub 2021 Dec 31.
- Derived from this study: PubMed 34890104Santiago-Torres M, Mull KE, Sullivan BM, Kwon D, Nollen NL, Zvolensky MJ, Bricker JB. Efficacy and utilization of an acceptance and commitment therapy-based smartphone application for smoking cessation among Black adults: secondary analysis of the iCanQuit randomized trial. Addiction. 2022 Mar;117(3):760-771. doi: 10.1111/add.15721. Epub 2021 Dec 9.
- Derived from this study: PubMed 34751662Bricker JB, Levin M, Lappalainen R, Mull K, Sullivan B, Santiago-Torres M. Mechanisms of Smartphone Apps for Cigarette Smoking Cessation: Results of a Serial Mediation Model From the iCanQuit Randomized Trial. JMIR Mhealth Uhealth. 2021 Nov 9;9(11):e32847. doi: 10.2196/32847.
- Derived from this study: PubMed 32955554Bricker JB, Watson NL, Mull KE, Sullivan BM, Heffner JL. Efficacy of Smartphone Applications for Smoking Cessation: A Randomized Clinical Trial. JAMA Intern Med. 2020 Nov 1;180(11):1472-1480. doi: 10.1001/jamainternmed.2020.4055.
- Individual participant dataSharing planned: No
Related trials for Smoking
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Recruiting
Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on Smoking
Tobacco Dependence
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonathan Bricker, Ph.D. principal investigator
Fred Hutchinson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Smartphone-delivered Intervention (SmartQuit) in people with Smoking, run by Fred Hutchinson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Jan 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
30-day Point Prevalence Abstinence, Complete-case (time frame: 12 months post randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02724462, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2021.